Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.06 USD
Change Today -0.05 / -1.22%
Volume 111.3K
AXGN On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

axogen inc (AXGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/15/15 - $5.74
52 Week Low
10/23/14 - $2.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AXOGEN INC (AXGN)

Related News

No related news articles were found.

axogen inc (AXGN) Related Businessweek News

No Related Businessweek News Found

axogen inc (AXGN) Details

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offers AxoTouch Two Point Discriminator, a measurement tool for determining innervation density and sensory function. The company’s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It markets its products in the United States, the United Kingdom, Singapore, Israel, Canada, Switzerland, Austria, and Spain. AxoGen, Inc. is headquartered in Alachua, Florida.

84 Employees
Last Reported Date: 03/5/15

axogen inc (AXGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $473.3K
Chief Financial Officer, General Counsel, Sen...
Total Annual Compensation: $326.8K
Senior Vice President of Sales
Total Annual Compensation: $384.3K
Compensation as of Fiscal Year 2014.

axogen inc (AXGN) Key Developments

AxoGen, Inc. Adopts Amended and Restated Bylaws

AxoGen, Inc.'s board adopted amended and restated bylaws of the company (the Bylaws), replacing the former amended and restated bylaws of the company in their entirety. The bylaws became effective immediately upon their adoption by the board. The Bylaws are substantially the same as the prior bylaws except the Board amended Section 3.2 to increase the number of directors serving on the Board from seven members to eight members.

AxoGen, Inc. Appoints Neels as Director

On August 26, 2015, AxoGen, Inc. entered into a Securities Purchase Agreement (the purchase agreement) with Essex Woodlands Fund IX, L.P. Upon the closing of the purchase of the shares, the Board elected Mr. Neels to fill such vacancy and serve on the Board until the 2016 annual meeting. Mr. Neels, age 67, has been an operating partner of ESSEX since February 2013. Mr. Neels currently serves as the Chairman of the Board of Directors for Oraya Therapeutics and serves on the Board of Directors for Entellus Medical, Endologix and Bioventus.

AxoGen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

AxoGen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $6,417,253 compared to $4,214,193 a year ago. Loss from operations was $2,153,269 compared to $2,297,744 a year ago. Net loss available to common shareholders was $3,190,873 or $0.13 basic and diluted per share compared to $3,741,471 or $0.21 basic and diluted per share a year ago. For the six months period, the company reported revenues of $11,368,569 compared to $7,352,449 a year ago. Loss from operations was $4,696,973 compared to $5,288,886 a year ago. Net loss available to common shareholders was $6,766,073 or $0.29 basic and diluted per share compared to $7,981,036 or $0.46 basic and diluted per share a year ago. Net cash used for operating activities was $6,010,955 compared to $5,719,999 a year ago. Purchase of property and equipment was $132,492 compared to $283,476 a year ago. Acquisition of intangible assets was $54,075 compared to $30,305 a year ago. Based on a  strong first half and the continued momentum the company is experiencing in the third quarter, the company is raising its revenue guidance and now expects 2015 full year revenue to exceed $25 million with annual gross margins in the mid to high 70% range.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXGN:US $4.06 USD -0.05

AXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $33.55 USD +0.82
Integra LifeSciences Holdings Corp $61.05 USD +1.53
Stryker Corp $96.46 USD +1.55
View Industry Companies

Industry Analysis


Industry Average

Valuation AXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AXOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at